The use of a probiotic strain of Lactobacillus rhamnosus and an oligosaccharide mixture which comprises 5-70 wt% of at least one N-acetylated oligosaccharide selected from the group comprising GalNAcαl,3Galβl,4Glc and Galβl,6GalNAcαl,3Galβl,4Glc, 20-90 wt% of at least one neutral oligosaccharide selected from the group comprising Galβl,6Gal, Galβl,6Galβl,4Glc Galβl,6Galβl,6Glc, Galβl,3Galβl,3Glc, Galβ 1,3Galβ 1,4GIc, Galβ 1,6Galβ 1,6Galβ 1,4GIc, Galβ 1,6Galβ 1,3Galβ 1,4GIc Galβl,3Galβl,6Galβl,4Glc and Galβ l,3Galβl,3Galβl, 4GIc and 5-50 wt% of at least one sialylated oligosaccharide selected from the group comprising NeuAcα2,3Galβl,4Glc and NeuAcα2,6Galβl,4Glc in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.
